RxDoctor Payments Data

Kevin Springer, APRN

Family · Henderson, NVNPI 1912953597

Payments from drug & device makers

$1,106in general payments, 2019–2025

Across 32 payments — averaging $34.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$302
  • Novo Nordisk$284
  • Pfizer$151
  • Dexcom, Inc.$138
  • Medtronic$73
  • Boehringer Ingelheim$59
  • plus $99 from 5 others
$209in research payments, 2019–2025

Across 2 payments — averaging $104.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Dexcom, Inc.$209

What the payments were for

  • Food & beverage$1,106100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,106 in reported general payments places this provider in the 70th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$28,919
Medicare patients
123
Services billed
361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban19$14,891
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$4,955
Atorvastatin Calcium160$1,302
Rosuvastatin Calcium41$751
Losartan Potassium89$571
Amlodipine Besylate89$569
Hydroxyzine Hcl18$546
Levothyroxine Sodium61$507
Ezetimibe15$362
Potassium Chloride11$349
Metformin Hcl29$318
ClopidogrelClopidogrel Bisulfate17$286
Omeprazole32$284
Montelukast Sodium35$274
Metformin Hcl ErMetformin Hcl29$273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$151$14,89119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,501 family providers in Nevada.

Other family in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →